187244-70-8

Basic information

• Product Name: 1H-Indole-3-acetic acid, 1-[(phenylmethoxy)carbonyl]-
• CAS NO: 187244-70-8
• Molecular Formula: C18H15NO4
• Molecular Weight: 309.321
• Mol File: 187244-70-8.mol
• Article Data: 7

Chemical Properties

• CAS DataBase Reference: 1H-Indole-3-acetic acid, 1-[(phenylmethoxy)carbonyl]-(CAS DataBase Reference)
• NIST Chemistry Reference: 1H-Indole-3-acetic acid, 1-[(phenylmethoxy)carbonyl]-(187244-70-8)
• EPA Substance Registry System: 1H-Indole-3-acetic acid, 1-[(phenylmethoxy)carbonyl]-(187244-70-8)

Safety Data

• Hazardous Substances Data: 187244-70-8(Hazardous Substances Data)

Upstream product

• 501-53-1 benzyl chloroformate 
• 87-51-4 indole-3-acetic acid 
• 22129-07-3 N-benzyloxycarbonylimidazole 
• 100-51-6 benzyl alcohol 

Downstream Products

• 919295-74-2 3-(3-diazo-2-oxo-propyl)-indole-1-carboxylic acid benzyl ester 
• 202932-23-8 3-[(S)-1-tert-Butoxycarbonylmethyl-2-((4S,5R)-4-methyl-2-oxo-5-phenyl-oxazolidin-3-yl)-2-oxo-ethyl]-indole-1-carboxylic acid benzyl ester 
• 202932-28-3 3-[(R)-1-(Benzyloxycarbonylamino-methyl)-2-((4S,5R)-4-methyl-2-oxo-5-phenyl-oxazolidin-3-yl)-2-oxo-ethyl]-indole-1-carboxylic acid benzyl ester 
• 202932-16-9 (4S,5R)-3-(1-benzyloxycarbonylindol-3-yl)acetyl-4-methyl-5-phenyl-1,3-oxazolidin-2-one 
• 851547-84-7 benzyl 3-(3-acetoxy-2-oxopropyl)-1H-indole-1-carboxylate 
• 851547-83-6 benzyl 3-(3-chloro-2-oxopropyl)-1H-indole-1-carboxylate 
• 875574-94-0 (S)-benzyl 3-(2-(5-(1,3-dioxolan-2-yl)-1-methoxy-1-oxopentan-2-ylamino)-2-oxoethyl)-1H-indole-1-carboxylate 
• 202932-18-1 3-Chlorocarbonylmethyl-indole-1-carboxylic acid benzyl ester 

Relevant articles and documents

2,3-substituted 2-azanorbornanes as polar β-turn mimetics

The design and synthesis of N-(3-indolylmethyl)-3-benzyl-2-azabicyclo[2.2.1]heptane-2-carboxamide (3) as a conformationally constrained non-peptide β-turn mimetic is described. Compound 3 is shown to mimic the Trp and Phe side chain conformation and the overall dipole moment of MEN10627 (2), a cyclic hexapeptide with a high NK-2 affinity. The tachykinin receptor affinities of 3 are evaluated and compared to those of MEN10627 and previously reported Trp-Phe mimetic 1.

Methods and Compositions for Treatment of Scleritis and Related Disorders

The present teachings relate to the field of anti-inflammatory substances and more particularly to compounds that are useful for the treatment of scleritis, a scleritis symptom, or a scleritis-related disorder. In one aspect, methods of treating scleritis, a scleritis symptom, or a scleritis-related disorder generally include administering to a subject a compound of Formula I: or a pharmaceutically acceptable salt, hydrate or ester thereof, wherein W1, W2, R1, L, X, Y, Z, and n1 are defined as described herein.

2-(4-Chlorobenzyl)-3-hydroxy-7,8,9,10-tetrahydrobenzo[H] quinoline-4-carboxylic acid (PSI-697): Identification of a clinical candidate from the quinoline salicylic acid series of P-selectin antagonists

P-selectin-PSGL-1 interaction causes rolling of leukocytes on the endothelial cell surface, which subsequently leads to firm adherence and leukocyte transmigration through the vessel wall into the surrounding tissues. P-selectin is upregulated on the surface of both platelets and endothelium in a variety of atherosclerosis-associated conditions. Consequently, inhibition of this interaction by means of a small molecule P-selectin antagonist is an attractive strategy for the treatment of atherosclerosis. High-throughput screening and subsequent analoging had led to the identification of compound 1 as the lead candidate. Herein, we report the continuation of this work and the discovery of a second-generation series, the tetrahydrobenzoquinoline salicylic acids. These compounds have improved pharmacokinetic properties, and a number of them have shown oral efficacy in mouse and rat models of atherogenesis and vascular injury. The lead 31 (PSI-697), is currently in clinical development for the treatment of atherothrombotic vascular events.